You are here

SBIR PHASE I TOPIC #446 - DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91023C00038
Agency Tracking Number: 75N91023C00038
Amount: $400,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 446
Solicitation Number: PHS-2023-1
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
6 BEECHTREE LANE
PLAINSBORO, NJ 08536-3702
United States
DUNS: 097940855
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL OHLMEYER
 (609) 275-3781
 michael.ohlmeyer@gmail.com
Business Contact
 MICHAEL OHLMEYER
Phone: (609) 275-3781
Email: michael.ohlmeyer@gmail.com
Research Institution
N/A
Abstract

New therapeutic approaches are urgently required for the treatment of high-risk neuroblastoma where patient outcomes have shown no improvement over recent decades. Many of the agents currently used clinically to arrest cancer cell proliferation of neuroblastoma do so by inducing cellular senescence, or a quasi-senescent state, in which treated neuroblastoma tumors evade chemotherapy. Relapse and disease progression from this therapy induced senescence (TIS)is a major problem and cause of mortality. This proposal aims to evaluate a new class of compounds that act by increasing the activity of a tumor suppressor phosphatase, PP2A. The novel PP2A activators will be senotherapeutic in two ways. First as senolytic agents by restoring sensitivity to apoptosis after TIS. Second, they will act as senomorphic agents by down regulating the expression of pro-inflammatory proteins (SASP) expressed by senescent neuroblastoma and other tumor associated cell types.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government